Does Retatrutide Suppress Appetite More Than Mounjaro or Ozempic?

Retatrutide has produced greater average weight loss in an early clinical trial than semaglutide and tirzepatide achieved in separate landmark studies. However, that does not yet prove that retatrutide suppresses appetite more strongly than Mounjaro, Ozempic or Wegovy.

The published retatrutide phase 2 trial measured changes in body weight—not a direct head-to-head comparison of hunger, cravings or calorie intake against these medicines. Retatrutide may affect both energy intake and energy expenditure, so its weight-loss results cannot be attributed entirely to reduced appetite.

Quick Answer

Retatrutide is expected to reduce appetite because it activates the GLP-1 and GIP receptors involved in fullness and food intake.

It also activates the glucagon receptor, which may influence energy expenditure, fat use and metabolism. This additional mechanism could help explain its substantial effect on body weight, but researchers have not yet established how much of the weight loss comes from:

• Reduced hunger.

• Earlier fullness.

• Lower calorie intake.

• Increased energy expenditure.

• Changes in how the body uses stored fuel.

A phase 3 trial is directly comparing retatrutide with tirzepatide, the active ingredient in Mounjaro and Zepbound. Its results are not yet available, with primary completion currently estimated for December 2026.

Retatrutide Appetite Suppression at a Glance

Question	What the Evidence Shows
Does retatrutide reduce appetite?	It is expected to reduce appetite through GLP-1 and GIP receptor activity, but published trials have focused mainly on weight loss rather than detailed appetite outcomes.
Is it proven to suppress appetite more than Mounjaro?	No. A direct phase 3 comparison is under way, but results are not yet available.
Is it proven to suppress appetite more than Ozempic or Wegovy?	No completed head-to-head trial has directly compared their effects on hunger or calorie intake.
Did retatrutide produce substantial weight loss?	Yes. Participants receiving 12 mg lost an average of 24.2% of their body weight after 48 weeks in the phase 2 trial.
Does greater weight loss prove stronger appetite suppression?	No. Retatrutide’s glucagon activity may also affect energy expenditure, substrate use and metabolism.
Can you currently obtain retatrutide legally?	Retatrutide remains investigational and is not approved or available for public use.

What Did the Retatrutide Trial Find?

The phase 2 obesity trial included 338 adults and compared several once-weekly doses of retatrutide with placebo.

After 48 weeks, average weight loss was:

• 8.7% with 1 mg.

• 17.1% with 4 mg.

• 22.8% with 8 mg.

• 24.2% with 12 mg.

• 2.1% with placebo.

The trial demonstrated a clear dose-related reduction in body weight. However, its primary endpoint was weight change at 24 weeks, with further weight-loss and safety outcomes assessed at 48 weeks. It was not designed to prove that retatrutide reduces hunger more than semaglutide or tirzepatide.

Is Retatrutide Available Yet?

No.

As of July 2026, retatrutide remains an investigational medicine in phase 3 clinical trials. It has not been approved by any regulatory agency and is legally available only to participants in authorised clinical studies.

Products advertised online as “research-grade”, compounded or unofficial retatrutide have not undergone the same checks for dose, purity, safety or effectiveness. The FDA has warned consumers not to purchase unapproved retatrutide products sold outside clinical trials.

Pharmacist’s Verdict

Retatrutide may ultimately prove more effective for weight loss than current GLP-1-based medicines, but greater weight loss does not automatically mean greater appetite suppression.

The most accurate conclusion is that retatrutide probably reduces food intake while also producing metabolic effects through glucagon receptor activation. Until direct comparative trial results are available, claims that it “kills hunger” more effectively than Mounjaro or Ozempic remain unproven.

How Do Retatrutide, Mounjaro and Ozempic Work?

Retatrutide, Mounjaro and Ozempic all influence hormone receptors involved in blood glucose regulation, appetite and body weight—but they do not work in exactly the same way.

• Ozempic and Wegovy contain semaglutide, which activates the GLP-1 receptor.

• Mounjaro contains tirzepatide, which activates both the GLP-1 and GIP receptors.

• Retatrutide activates GLP-1, GIP and glucagon receptors within a single investigational molecule.

Mechanisms at a Glance

Medicine	Active Ingredient	Receptors Targeted	Current Status
Ozempic	Semaglutide	GLP-1	Approved primarily for type 2 diabetes
Wegovy	Semaglutide	GLP-1	Approved for weight management
Mounjaro	Tirzepatide	GIP and GLP-1	Approved for type 2 diabetes and weight management in the UK
Retatrutide	Retatrutide	GIP, GLP-1 and glucagon	Investigational; not yet approved

Ozempic and Wegovy contain the same active ingredient, but they are marketed for different indications and use different dosing schedules. Similarly, tirzepatide is sold as Mounjaro in the UK for both diabetes and eligible weight-management patients.

What Does the GLP-1 Receptor Do?

GLP-1 is a naturally occurring gut hormone released after eating.

Activating the GLP-1 receptor can:

• Increase feelings of fullness.

• Reduce hunger and food cravings.

• Lower food intake.

• Stimulate insulin release when blood glucose is elevated.

• Slow gastric emptying, particularly earlier in treatment.

These effects help explain why semaglutide can reduce calorie intake and body weight. The EMA describes Wegovy as regulating appetite by increasing fullness while reducing hunger, cravings and food intake.

What Does GIP Add?

GIP—glucose-dependent insulinotropic polypeptide—is another hormone released from the gut after eating.

Tirzepatide activates both GIP and GLP-1 receptors. Together, these actions support glucose-dependent insulin release and reduce appetite, helping people manage blood glucose and body weight.

However, it is difficult to separate precisely how much of tirzepatide’s weight-loss effect comes from:

• GLP-1 receptor activity.

• GIP receptor activity.

• Interactions between the two pathways.

• Reduced food intake.

• Changes in metabolism and insulin sensitivity.

It would therefore be too simplistic to say that Mounjaro works better than semaglutide merely because it activates two receptors instead of one.

What Does the Glucagon Receptor Add?

Retatrutide adds glucagon receptor activity to the GIP and GLP-1 pathways.

Glucagon is traditionally associated with maintaining blood glucose by signalling the liver to release stored energy. In a combined treatment such as retatrutide, researchers believe glucagon receptor activity may also influence:

• Energy expenditure.

• Fat and carbohydrate metabolism.

• The use of stored energy.

• Overall energy balance.

The phase 2 researchers proposed that adding glucagon receptor agonism to GIP and GLP-1 activity may partly explain retatrutide’s substantial effect on body weight. However, the relative contribution of reduced appetite versus increased energy expenditure has not yet been established.

Does Targeting Three Receptors Make Retatrutide Stronger?

Not automatically.

The number of receptors targeted does not tell us:

• How strongly each receptor is activated.

• Which receptor contributes most to appetite reduction.

• How an individual will respond.

• Which dose offers the best balance of benefits and adverse effects.

• Whether greater weight loss results primarily from eating less.

A triple agonist is not simply three medicines added together. Retatrutide is one molecule engineered to activate three receptor pathways with a particular pharmacological profile.

Its phase 2 and phase 3 weight-loss results are substantial, but receptor count alone cannot prove that it reduces hunger more than tirzepatide or semaglutide. Retatrutide’s direct phase 3 comparison with tirzepatide is still under way, with completion estimated for December 2026.

The Key Difference

The medicines can be summarised as follows:

• Semaglutide: primarily reduces food intake through GLP-1-related appetite and satiety effects.

• Tirzepatide: combines GIP and GLP-1 activity, producing effects on appetite, glucose regulation and body weight.

• Retatrutide: combines GIP, GLP-1 and glucagon activity, potentially affecting both energy intake and energy expenditure.

Pharmacist’s Perspective

Retatrutide’s triple-receptor mechanism makes it scientifically different from Mounjaro and Ozempic, but different does not automatically mean more appetite suppression.

Its additional glucagon activity may help explain why weight loss has been so substantial. Until direct appetite and calorie-intake comparisons are available, however, we cannot determine whether retatrutide reduces hunger more powerfully—or whether it achieves part of its effect through greater changes in energy expenditure and metabolism.

Does More Weight Loss Mean Stronger Appetite Suppression?

Not necessarily.

Body-weight change reflects the overall balance between:

• Calories consumed.

• Energy used by the body.

• Changes in appetite and food cravings.

• Changes in fullness and meal size.

• Metabolic effects on fat and carbohydrate use.

• Physical activity and lifestyle support.

• Treatment dose, duration and adherence.

A medicine may therefore produce greater weight loss without reducing hunger by exactly the same proportion.

This distinction matters particularly for retatrutide because its glucagon receptor activity may affect energy expenditure and substrate utilisation, as well as food intake. Researchers have proposed these mechanisms as possible explanations for its substantial weight-loss results, but their individual contributions have not yet been quantified.

How Much Weight Loss Occurred in the Major Trials?

The best-known obesity trials reported the following average changes:

Medicine	Trial	Dose	Trial Length	Average Weight Change
Retatrutide	Phase 2 obesity trial	12 mg	48 weeks	−24.2%
Tirzepatide	SURMOUNT-1	15 mg	72 weeks	−20.9%
Semaglutide	STEP 1	2.4 mg	68 weeks	−14.9%

Retatrutide produced the largest headline figure, but these results came from three separate clinical trials. The participants, study durations, dose-escalation schedules, statistical methods and lifestyle programmes were not identical.

The figures therefore cannot be used to conclude that retatrutide suppresses appetite:

• 24% more strongly than another medicine.

• Almost twice as effectively as semaglutide.

• More powerfully than tirzepatide in every person.

• Faster or more consistently in ordinary clinical use.

They show that each medicine produced substantial weight loss within its own trial.

What Did the Trials Actually Measure?

The principal obesity trials were designed mainly to measure body-weight change, not to compare subjective appetite suppression.

The retatrutide phase 2 trial assessed:

• Percentage change in body weight.

• The proportion of participants reaching specified weight-loss thresholds.

• Safety and adverse effects.

It was not a completed head-to-head study against Mounjaro, Ozempic or Wegovy, and appetite ratings were not the primary endpoint.

Similarly, the landmark STEP 1 and SURMOUNT-1 trials focused primarily on weight loss rather than establishing which medicine produced the strongest day-to-day reduction in hunger.

Weight Loss Is Not an Appetite Score

Greater weight loss may suggest that a medicine has a powerful effect on overall energy balance. It does not reveal exactly:

• How hungry participants felt.

• Whether cravings disappeared completely.

• How many calories they consumed.

• Whether fullness lasted longer after meals.

• Whether metabolic energy expenditure also changed.

• Whether the effect would feel stronger to an individual patient.

Statements such as “retatrutide kills hunger more than Mounjaro” go beyond the evidence currently available.

What Do We Know About Mounjaro vs Wegovy?

Tirzepatide and semaglutide have now been compared directly for weight management.

In the 72-week SURMOUNT-5 trial, participants receiving tirzepatide lost an average of 20.2% of their body weight, compared with 13.7% among those receiving semaglutide. Tirzepatide was superior for body-weight and waist-circumference reduction.

However, even this direct trial does not mean every participant experienced stronger subjective appetite suppression with tirzepatide. The primary outcome was weight change, not a detailed comparison of hunger, cravings or food intake.

This illustrates why weight-loss superiority and appetite superiority should not be treated as identical claims.

Why Trial Duration Matters

Retatrutide participants receiving the higher doses were still losing weight when the 48-week phase 2 trial ended, suggesting that the average result may not have reached a plateau.

However, that does not make direct comparisons with longer 68- or 72-week trials straightforward.

A longer study gives participants:

• More time at their maintenance dose.

• More time to lose weight.

• More opportunity to discontinue treatment.

• More time for appetite effects to change or reach a plateau.

Comparing headline percentages without considering these differences can create a misleading impression of precision.

Does Faster Weight Loss Prove Less Hunger?

No.

Rapid weight loss can result from a combination of:

• Markedly reduced food intake.

• Gastrointestinal side effects that make eating difficult.

• Changes in energy expenditure.

• Loss of water, fat and lean tissue.

• Differences in starting weight.

• Dose escalation and individual responsiveness.

Nausea or difficulty eating should also not be confused with healthy appetite regulation. Feeling too unwell to eat is an adverse effect, not evidence that a medicine is working optimally.

Pharmacist’s Perspective

The available trials show that retatrutide is a highly potent investigational weight-loss medicine.

They do not yet show that it suppresses hunger more strongly than Mounjaro or Ozempic.

Its greater headline weight reduction may reflect a combination of reduced energy intake and glucagon-related metabolic effects. Until direct comparative evidence measures hunger, cravings and calorie intake, stronger appetite suppression remains a plausible possibility—not a proven fact.

Does Retatrutide Increase Energy Expenditure or “Speed Up Metabolism”?

Possibly—but this has not yet been demonstrated clearly enough to say that retatrutide makes people burn substantially more calories.

Retatrutide activates the glucagon receptor in addition to the GLP-1 and GIP receptors targeted by existing medicines. Researchers believe this extra pathway may influence:

• Energy expenditure.

• Fat and carbohydrate use.

• The release and use of stored energy.

• Meal size and food intake.

• The body’s response to weight loss.

However, the published phase 2 obesity trial did not directly establish how much retatrutide changed daily calorie expenditure. The researchers described increased energy expenditure and altered substrate use as possible contributors to its weight-loss effect—not confirmed explanations.

What Is Energy Expenditure?

Energy expenditure is the total amount of energy the body uses.

It includes:

• Resting energy expenditure: the calories needed to maintain breathing, circulation and other basic functions.

• Diet-induced thermogenesis: the energy used to digest and process food.

• Physical activity: exercise and ordinary daily movement.

• Adaptive changes: reductions or increases in energy use that can occur during weight loss.

When someone loses a substantial amount of weight, their body usually requires fewer calories. The body may also adapt by becoming more energy-efficient, which can make continued weight loss increasingly difficult.

A medicine that preserves or increases energy expenditure could theoretically help counteract part of this adaptation. Whether retatrutide produces a clinically important effect of this kind in humans remains under investigation.

Why Might Glucagon Affect Energy Use?

Glucagon is commonly known as the hormone that helps prevent blood glucose from becoming too low by signalling the liver to release stored energy.

Its wider role is more complex. Glucagon receptor activation may also influence:

• Liver metabolism.

• Fat oxidation.

• Heat production.

• Amino-acid metabolism.

• Energy expenditure.

• Signals involved in meal size.

Retatrutide combines glucagon activity with GLP-1 and GIP activity. The GLP-1 and GIP components help control blood glucose and food intake, while the glucagon component may add effects on energy metabolism.

This balance is important because glucagon activity on its own could increase blood glucose. Retatrutide is designed so that its combined incretin activity helps offset that effect while potentially retaining some of glucagon’s metabolic actions.

Proposed Effects vs Proven Effects

Claim	What We Currently Know
Retatrutide increases energy expenditure	Biologically plausible, but the size and clinical importance of the effect have not yet been established publicly in human trials.
Retatrutide burns more fat	Large reductions in body fat and liver fat have been observed, but this does not prove a direct fat-burning effect independent of weight loss and reduced intake.
Retatrutide speeds up metabolism	This is an oversimplified marketing phrase. Specific changes in energy expenditure and fuel use require direct measurement.
Retatrutide works through more than appetite suppression	Likely, but the relative contribution of appetite, calorie intake and energy expenditure remains uncertain.
Retatrutide prevents metabolic slowing during weight loss	Not yet established.

Has Retatrutide’s Effect on Calorie Burning Been Studied Directly?

A dedicated phase 1 study enrolled 85 adults with obesity to examine retatrutide’s effects on:

• Calorie intake.

• Appetite.

• Energy expenditure.

• Energy metabolism during calorie restriction.

The study was completed in August 2025, but results have not yet been publicly posted on the ClinicalTrials.gov record. Until these findings are available, claims about precisely how much retatrutide increases calorie expenditure remain speculative.

This study is particularly relevant because it may help answer whether retatrutide’s unusually large weight-loss effect comes primarily from:

• People eating substantially less.

• Greater energy expenditure.

• A combination of both.

Does Retatrutide Specifically Target Body Fat?

The phase 2 obesity trial showed substantial reductions in overall body weight and waist circumference.

A related substudy involving participants with metabolic dysfunction-associated steatotic liver disease also found major reductions in liver fat. At 24 weeks, average liver-fat reductions exceeded 80% in the 8 mg and 12 mg groups, and many participants reached a liver-fat level within the normal range.

These findings show that retatrutide can produce substantial changes in fat stores.

They do not prove that the medicine selectively “melts fat” or protects all lean tissue. Reductions in liver fat were associated with changes in body weight, abdominal fat and metabolic measures, so several connected processes may have contributed.

Does Retatrutide Give You More Energy?

There is no reliable evidence that retatrutide produces a stimulant-like increase in energy.

Some people may report feeling more energetic as their blood glucose, mobility or general health improves. Others may feel more tired because they are:

• Eating considerably fewer calories.

• Experiencing nausea or other adverse effects.

• Losing weight rapidly.

• Struggling to consume enough carbohydrate, protein or fluid.

• Losing some lean body mass alongside fat.

Anecdotes describing “energy through the roof” cannot tell us what most people will experience.

Feeling less hungry is also different from feeling energetic. Someone can have very little appetite while simultaneously feeling weak or fatigued because their calorie and nutrient intake is too low.

Does Glucagon Mean Retatrutide Raises Blood Sugar?

Glucagon receptor activation can promote glucose release from the liver.

However, retatrutide simultaneously activates GLP-1 and GIP receptors, which support glucose-dependent insulin secretion and blood-glucose control. Clinical trials in people with obesity and type 2 diabetes have shown improvements in glucose-related outcomes rather than an overall worsening of glycaemic control.

The combined effect of the three receptor pathways cannot be predicted by considering glucagon in isolation.

Pharmacist’s Perspective

Retatrutide may affect energy expenditure and fuel metabolism in ways that distinguish it from semaglutide and tirzepatide.

However, it is too early to describe it confidently as a medicine that “speeds up the metabolism” or burns a specific number of additional calories.

The most defensible conclusion is that retatrutide probably acts on both sides of energy balance:

• Reducing energy intake through appetite-related pathways.

• Potentially influencing energy expenditure and substrate use through glucagon receptor activity.

We do not yet know how much each mechanism contributes to its overall weight-loss effect.

Can Retatrutide Suppress Appetite Too Much?

Potentially.

Reducing hunger can help people maintain a calorie deficit, but appetite suppression becomes a concern when someone can no longer consume enough food, fluid, protein or essential nutrients to support their health.

Retatrutide trials have not established a precise level of appetite suppression that is “too much”. They have, however, shown very substantial weight loss and dose-related gastrointestinal effects, particularly at higher doses.

In the phase 2 obesity trial:

• Gastrointestinal adverse effects were more common at higher doses.

• Nausea, diarrhoea, vomiting and constipation occurred most often during dose escalation.

• Between 6% and 16% of participants receiving retatrutide discontinued treatment because of adverse effects.

• Thirteen retatrutide participants reached a BMI of 22 or lower.

• Eight participants had protocol-directed dose reductions because their BMI had fallen.

• No participant’s BMI fell below 19.

These findings do not prove that retatrutide commonly causes dangerous or uncontrolled appetite loss. They do show why dose escalation, nutritional monitoring and individual treatment goals matter when a medicine produces unusually large reductions in body weight.

Appetite Suppression vs Feeling Too Unwell to Eat

Healthy appetite regulation and gastrointestinal intolerance are not the same thing.

A useful appetite effect may involve:

• Feeling satisfied with a smaller portion.

• Experiencing fewer food cravings.

• Remaining full between meals.

• Finding it easier to follow an appropriate eating plan.

A concerning response may involve:

• Persistent nausea whenever food is attempted.

• Repeated vomiting.

• Being unable to finish even very small meals.

• Avoiding food because eating causes discomfort.

• Drinking too little because of fullness or nausea.

• Rapid weakness, dizziness or loss of physical function.

Losing weight because hunger is more manageable is different from losing weight because side effects make eating difficult.

When Does Reduced Appetite Become a Nutritional Problem?

Appetite suppression may be excessive when it consistently prevents someone from meeting basic nutritional needs.

Warning signs can include:

• Regularly eating only one very small meal per day.

• Struggling to consume protein-rich foods.

• Depending mainly on crackers, toast or other bland foods for long periods.

• Persistent dizziness or light-headedness.

• Increasing weakness or poor exercise tolerance.

• Recurrent dehydration.

• Hair shedding, brittle nails or other possible signs of nutritional deficiency.

• Constipation that becomes severe or persistent.

• Continuing to lose weight beyond the agreed treatment target.

• Feeling unable to control the pace of weight loss.

These symptoms are not specific to retatrutide and may have several causes. They should prompt clinical review rather than attempts to compensate with random supplements.

Does Retatrutide Cause Muscle Loss?

Weight loss generally includes a combination of fat mass and lean mass.

A 2025 body-composition substudy in adults with type 2 diabetes found that retatrutide produced substantial reductions in total fat mass. The proportion of lean mass lost relative to total weight loss was reported to be similar to that seen with other obesity treatments, rather than disproportionately high.

This is reassuring, but it does not mean that muscle loss cannot occur.

Important limitations include:

• The substudy involved people with type 2 diabetes.

• It assessed one clinical-trial population.

• “Lean mass” includes more than skeletal muscle.

• Similar proportional loss can still represent a meaningful absolute amount when total weight loss is very large.

• Body composition does not fully show changes in strength or physical function.

The concern is therefore not that retatrutide has been proven to uniquely destroy muscle. It is that large and rapid weight loss can include lean tissue, particularly where calorie intake, protein intake and physical activity become very low.

How Can Lean Mass Be Supported During Weight Loss?

A joint advisory from major nutrition and obesity organisations recommends combining GLP-1-based treatment with strategies intended to preserve muscle and nutritional adequacy, including appropriate dietary protein and resistance exercise. Protein intake alone is unlikely to provide the same benefit without strength-based activity.

Practical priorities include:

Prioritise Protein

When appetite is limited, include a protein source early in the meal rather than filling up entirely on low-protein foods.

Options may include:

• Eggs.

• Greek yoghurt or cottage cheese.

• Fish.

• Chicken or lean meat.

• Tofu or tempeh.

• Beans, chickpeas and lentils.

• A suitable protein drink when ordinary food is difficult to manage.

Individual protein needs vary according to body size, age, kidney function, activity and medical history. Someone with kidney disease or another relevant condition should seek personalised advice rather than adopting a high-protein target independently.

Include Resistance Exercise

Strength training provides the muscles with a reason to be retained during weight loss.

Depending on ability, this may include:

• Resistance bands.

• Body-weight movements.

• Free weights.

• Weight machines.

• Supervised rehabilitation exercises.

The programme should be appropriate for the person’s current fitness, joint health and medical circumstances.

Use Smaller, Nutrient-Dense Meals

When large meals are uncomfortable, smaller servings may be more realistic.

Try to include:

• Protein.

• Fruit or vegetables.

• A source of carbohydrate where tolerated.

• Some healthy fat.

• Regular fluids.

The aim is not to force large meals. It is to obtain more nutritional value from the smaller quantity that can be eaten comfortably.

Stay Hydrated

Reduced food intake, vomiting and diarrhoea can all lower fluid intake or increase fluid loss.

Seek advice if you experience:

• Very dark urine.

• Infrequent urination.

• Persistent dizziness.

• Difficulty keeping fluids down.

• Confusion or marked weakness.

Is Faster Weight Loss Always Better?

No.

The most appropriate rate and extent of weight loss depend on:

• Starting weight and BMI.

• Existing health conditions.

• Age and muscle reserve.

• Treatment goals.

• Nutritional intake.

• Strength and physical function.

• Adverse effects.

• Whether weight is still falling after the intended target has been reached.

The objective of obesity treatment is not to produce the lowest possible number on the scale. It is to improve health while maintaining adequate nutrition, strength and quality of life.

Retatrutide’s phase 3 TRIUMPH-1 trial has now reported topline average weight loss of 28.3% at 80 weeks with the 12 mg dose, with some participants losing considerably more. Retatrutide nevertheless remains investigational, and full peer-reviewed phase 3 data and longer-term safety assessment are still important.

What Should Happen if Appetite Suppression Is Excessive?

Within a properly supervised clinical trial or future licensed treatment programme, concerns may lead to review of:

• Dose escalation.

• The current maintenance dose.

• Gastrointestinal adverse effects.

• Hydration.

• Protein and calorie intake.

• Weight-loss goals.

• Muscle strength and physical function.

• Blood tests for possible nutritional deficiencies.

Someone should not independently adjust an investigational medicine or buy a lower-strength product from an unregulated source.

Because retatrutide is not approved for public use, anyone taking a product sold online as retatrutide is doing so without the safeguards of regulated prescribing, verified manufacturing and trial monitoring.

Pharmacist’s Perspective

Retatrutide’s ability to produce substantial weight loss makes nutritional monitoring particularly important.

The evidence does not show that retatrutide uniquely causes disproportionate muscle loss or that appetite suppression will become excessive for everyone. However, a medicine should not leave someone persistently unable to eat, hydrate or maintain strength.

Successful treatment should mean more than losing the greatest possible amount of weight. It should also preserve nutrition, muscle function and overall health.

Retatrutide Side Effects and Safety

Retatrutide has produced substantial weight loss in clinical trials, but stronger effects do not automatically mean a better treatment for every person.

Its most common adverse effects have involved the digestive system, particularly while the dose is being increased. Retatrutide remains investigational, so its full long-term safety profile has not yet been established.

What Are the Most Common Retatrutide Side Effects?

The most commonly reported effects include:

• Nausea.

• Diarrhoea.

• Constipation.

• Vomiting.

• Abdominal or digestive discomfort.

In the phase 2 obesity trial, gastrointestinal effects were generally mild to moderate, occurred more frequently at higher doses and were most common during dose escalation. Starting at a lower dose reduced some of these problems.

Lilly’s topline phase 3 TRIUMPH-1 results reported the following rates:

Side Effect	4 mg	9 mg	12 mg	Placebo
Nausea	28.6%	38.4%	42.4%	14.8%
Diarrhoea	25.2%	34.1%	32.0%	13.5%
Constipation	23.8%	25.9%	26.1%	10.9%
Vomiting	10.6%	22.8%	25.3%	4.8%

These figures show a broadly dose-related pattern, particularly for nausea and vomiting. However, the phase 3 results were announced by the manufacturer in May 2026 and have not yet been fully published in a peer-reviewed paper.

How Often Did People Stop Treatment?

In the phase 2 trial, 6%–16% of retatrutide participants stopped treatment because of adverse effects, compared with none of the placebo participants. Gastrointestinal symptoms were the most frequent reason for discontinuation.

In TRIUMPH-1, discontinuation because of adverse effects occurred in:

• 4.1% of participants receiving 4 mg.

• 6.9% receiving 9 mg.

• 11.3% receiving 12 mg.

• 4.9% receiving placebo.

The lower-dose group achieved less weight loss but also had a lower observed discontinuation rate than the higher-dose groups. This highlights why the most effective dose is not automatically the highest dose someone can tolerate.

What Is Dysesthesia?

TRIUMPH-1 also reported dysesthesia, an altered skin sensation that may be described as tingling, burning, numbness or unusual sensitivity.

It occurred in:

• 5.1% of participants taking 4 mg.

• 12.3% taking 9 mg.

• 12.5% taking 12 mg.

• 0.9% taking placebo.

Lilly reported that most cases were mild to moderate and that most participants continued treatment. The mechanism and longer-term importance of this effect are not yet clear.

Does Retatrutide Increase Heart Rate?

A dose-dependent increase in heart rate was observed in the phase 2 trial.

The increase peaked at approximately 24 weeks and declined afterwards. The available study did not establish that this translated into a higher rate of serious cardiovascular events, but continued cardiovascular monitoring remains important while retatrutide is being evaluated.

Someone experiencing a persistent racing heartbeat, chest pain, fainting or significant breathlessness should seek urgent medical assessment rather than assuming it is a normal appetite-suppressing effect.

What Serious Risks Are Known?

It is too early to provide a complete list of established serious retatrutide risks.

Retatrutide has not yet received a final product licence, approved prescribing information or the scale of post-marketing safety data available for semaglutide and tirzepatide.

Current trials are assessing:

• Gastrointestinal tolerability.

• Heart-rate and cardiovascular effects.

• Gallbladder and pancreatic events.

• Kidney outcomes and dehydration.

• Changes in blood glucose.

• Nutritional and body-composition effects.

• Longer-term discontinuation and safety.

The absence of a clear signal in an early trial does not prove that a rare adverse effect cannot occur. Rare risks may only become apparent after much larger numbers of people have used an approved medicine for longer periods.

Can Vomiting or Diarrhoea Affect the Kidneys?

Persistent vomiting or diarrhoea can lead to dehydration, regardless of which medicine caused it.

Possible warning signs include:

• Very dark urine.

• Urinating much less frequently.

• Persistent dizziness.

• Fainting.

• Confusion.

• Being unable to keep fluids down.

• Marked weakness.

These symptoms require prompt medical advice. Kidney problems reported during rapid weight loss cannot automatically be attributed directly to retatrutide, because dehydration, dietary changes and pre-existing conditions may also contribute.

Are Bone Fractures a Proven Retatrutide Side Effect?

No.

Some media articles have connected rapid weight loss with frailty, reduced bone strength or fractures. These are legitimate concerns during major weight loss—particularly in older adults or people losing muscle—but retatrutide has not been shown to directly cause osteoporosis or fractures.

Potential contributors during rapid weight reduction may include:

• Loss of lean mass.

• Inadequate protein intake.

• Low calcium or vitamin D intake.

• Reduced resistance exercise.

• Existing osteoporosis.

• Very low calorie intake.

• Falls caused by weakness or dizziness.

It is more accurate to discuss bone and muscle health as potential consequences of substantial or poorly supported weight loss rather than as confirmed direct toxic effects of retatrutide.

Why Online “Research” Retatrutide Is Particularly Risky

Retatrutide remains investigational and is legally available only within authorised clinical trials.

Products advertised online as:

• “Research-grade retatrutide”.

• “Not for human consumption”.

• Compounded retatrutide.

• Retatrutide peptide powder.

• Reconstituted or premixed injections.

have not been approved as retatrutide medicines.

The FDA states that retatrutide cannot legally be used in compounding in the United States and has warned companies selling it directly to consumers. Products labelled for research purposes may be of unknown quality and could be harmful.

Buying from an unofficial supplier means there may be no reliable assurance of:

• The ingredient’s identity.

• The actual dose.

• Sterility.

• Purity.

• Appropriate storage.

• Freedom from contamination.

• Accurate instructions.

• Safe dose escalation.

Laboratory testing advertised by a seller is not equivalent to regulatory approval, validated manufacturing controls or clinical monitoring.

Why Clinical-Trial Monitoring Matters

Participants receiving retatrutide in trials are monitored through structured protocols that may include:

• Gradual dose escalation.

• Medical assessment.

• Adverse-event reporting.

• Blood tests.

• Weight and BMI monitoring.

• Dose reduction or discontinuation criteria.

• Nutritional and cardiovascular assessment.

Someone injecting an unofficial product does not have these safeguards and may not even be receiving the molecule or dose stated on the label.

Pharmacist’s Perspective

The currently available evidence suggests that retatrutide’s most frequent adverse effects are gastrointestinal and become more common at higher doses.

The phase 3 results are encouraging, but they remain topline manufacturer data until the full trial is peer reviewed. Important questions about long-term safety, rare adverse effects and the best balance between weight loss and tolerability remain unanswered.

Retatrutide should not be obtained through social media, peptide websites, unregulated clinics or products labelled for research use. Its impressive trial results do not make unofficial versions safe.

Frequently Asked Questions

Does retatrutide suppress appetite more than Mounjaro?

It has not yet been proven.

Retatrutide produced substantial weight loss in its phase 2 and phase 3 obesity trials, but those studies did not directly compare its effect on hunger or calorie intake with Mounjaro.

The phase 3 TRIUMPH-5 trial is directly comparing retatrutide with tirzepatide, the active ingredient in Mounjaro. The study is active but has not yet posted results, with completion estimated for December 2026.

Is retatrutide stronger than Ozempic or Wegovy?

Retatrutide has produced greater average weight loss than semaglutide achieved in separate landmark trials.

In Lilly’s phase 3 TRIUMPH-1 trial, participants receiving 12 mg retatrutide lost an average of 28.3% of their body weight over 80 weeks. However, this was not a direct comparison with Ozempic or Wegovy, and it does not prove that the difference was caused solely by stronger appetite suppression.

Retatrutide may affect both food intake and energy expenditure, while semaglutide primarily acts through GLP-1-related effects on appetite, fullness and glucose regulation.

Does retatrutide completely remove hunger?

It should not be assumed to eliminate hunger completely.

People respond differently to appetite-regulating medicines. Some may experience a substantial reduction in cravings and meal size, while others may still feel hungry at regular intervals.

Published trials have not shown that every participant stopped experiencing hunger. Complete loss of appetite may also be undesirable if it prevents someone from meeting basic nutritional and hydration needs.

Why might retatrutide cause more weight loss?

Retatrutide activates:

• GLP-1 receptors.

• GIP receptors.

• Glucagon receptors.

Its GLP-1 and GIP activity may reduce food intake, while glucagon receptor activation may influence energy expenditure and the way the body uses stored fuel.

Researchers have proposed that these combined effects may explain its substantial weight-loss results, but the precise contribution of each mechanism remains uncertain.

Does retatrutide speed up metabolism?

Possibly, but “speeding up metabolism” is an oversimplification.

Glucagon receptor activation may influence energy expenditure, fat oxidation and substrate use. However, there is not yet enough published human evidence to state how many additional calories retatrutide causes someone to burn or how clinically important this effect is.

Its weight-loss results should not be described as proof that it simply “melts fat” or permanently increases metabolic rate.

Can retatrutide make you eat too little?

Potentially.

Appetite suppression becomes a concern if it results in:

• Regularly skipped meals.

• Inadequate protein intake.

• Persistent dehydration.

• Weakness or dizziness.

• Continued weight loss beyond the intended target.

• Difficulty maintaining muscle and physical function.

Nausea, vomiting or discomfort that prevents eating should be treated as an adverse effect rather than desirable appetite control.

Does retatrutide cause fatigue?

Fatigue may occur during significant weight loss, but it is not possible to assume that retatrutide directly causes every episode.

Possible contributing factors include:

• Eating too few calories.

• Dehydration.

• Vomiting or diarrhoea.

• Inadequate carbohydrate or protein intake.

• Rapid weight loss.

• Loss of lean tissue.

• Nutritional deficiencies.

• Another medical condition.

Persistent or severe fatigue should prompt clinical review rather than simply adding supplements.

Is retatrutide a GLP-3 medicine?

No.

“GLP-3” is an informal and scientifically inaccurate nickname. Retatrutide is more accurately described as a triple hormone-receptor agonist because it activates GIP, GLP-1 and glucagon receptors.

Is retatrutide approved in the UK?

No.

Retatrutide remains an investigational medicine and has not been approved for UK use. The MHRA states that products sold outside authorised clinical trials are likely to be illegal and potentially dangerous.

An agreed paediatric investigation plan is part of the development process, but it is not the same as marketing authorisation or approval for prescribing.

When will retatrutide become available?

There is no confirmed public launch date.

Several phase 3 trials have reported results, while other studies remain under way. Availability will depend on completion of the clinical programme, submission to regulators and approval of its benefits, risks, manufacturing and prescribing information.

Can you buy compounded or research-grade retatrutide?

You should not.

Retatrutide products sold online have not been approved or verified for dose, purity, sterility or safety. The MHRA has seized unlicensed products claiming to contain retatrutide, while the FDA warns that research-labelled versions may be of unknown quality and harmful.

A vial labelled “not for human consumption” does not become safe because a seller provides injection instructions or a laboratory certificate.

What should you do if appetite suppression becomes excessive?

Within an authorised clinical trial, contact the trial team.

Signs that require review include:

• Repeated vomiting.

• Being unable to keep fluids down.

• Severe or persistent abdominal symptoms.

• Fainting or marked dizziness.

• Rapid weakness or reduced physical function.

• Continuing to lose weight beyond the agreed target.

• Being unable to consume adequate food or protein.

Do not independently change the dose of an investigational medicine or try to correct severe appetite suppression using unregulated products.

---

Final Verdict

Retatrutide has produced some of the largest average weight reductions yet reported for an investigational obesity medicine. Lilly’s TRIUMPH-1 phase 3 results reported average weight loss of 28.3% over 80 weeks with the 12 mg dose.

However, this does not prove that retatrutide suppresses appetite more strongly than Mounjaro, Ozempic or Wegovy.

The published evidence supports three conclusions:

1. Retatrutide probably reduces food intake through its GLP-1 and GIP activity.

2. Its glucagon activity may add metabolic effects, including changes in energy expenditure and fuel use.

3. No completed direct trial has yet shown that people feel less hungry on retatrutide than on Mounjaro.

The most accurate answer is therefore:

Retatrutide may ultimately prove more powerful for overall weight loss, but stronger appetite suppression has not yet been demonstrated directly.

More appetite suppression is not automatically better. Effective treatment should help regulate food intake while preserving hydration, nutritional adequacy, muscle function and quality of life.

Retatrutide remains unapproved and should not be purchased from peptide websites, social-media sellers or clinics offering unofficial compounded versions.

Further Reading

• Retatrutide: The “Godzilla Jab” — What You Need to Know

• Retatrutide vs Ozempic vs Mounjaro: What’s the Difference?

• How Does Retatrutide Work? GLP-1, GIP and Glucagon Explained

• Nutrient Deficiencies Common on GLP-1 Medications

• Can You Take Supplements With Mounjaro, Ozempic or Wegovy?

• Can Ozempic or Mounjaro Cause Anaemia?

• How to Maintain Energy on Mounjaro or Ozempic

---

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389:514–526.

2. ClinicalTrials.gov. A Study of Retatrutide Compared With Tirzepatide in Adults Who Have Obesity (TRIUMPH-5). Trial identifier: NCT06662383.

3. Eli Lilly and Company. Retatrutide delivered powerful weight loss in pivotal phase 3 obesity trial. TRIUMPH-1 topline results. May 2026.

4. Eli Lilly and Company. Additional phase 3 retatrutide results in obesity, type 2 diabetes, knee osteoarthritis and obstructive sleep apnoea. June 2026.

5. Rosenstock J, et al. Retatrutide in adults with type 2 diabetes: a randomised, double-blind, phase 2 trial. The Lancet. 2023.

6. Sanyal AJ, et al. Effects of retatrutide on liver fat in people with metabolic dysfunction-associated steatotic liver disease. Nature Medicine. 2024.

7. ClinicalTrials.gov. A Study of Retatrutide on Energy Metabolism in Participants With Obesity. Trial identifier: NCT06313528.

8. US Food and Drug Administration. FDA’s Concerns With Unapproved GLP-1 Drugs Used for Weight Loss.

9. Medicines and Healthcare products Regulatory Agency. Enforcement action involving unlicensed weight-loss medicines, including retatrutide. 2026.

---

About the Author

Jon Wright is a Clinical Pharmacist and Co-Founder of Arbor Vitamins.

He writes evidence-led guidance on medicines, supplements and nutrient interactions, with a focus on separating established clinical evidence from early research and marketing claims.

Last reviewed: July 2026.

---

This article is for general information only and does not replace individual medical advice. Retatrutide remains an investigational medicine and is not approved for routine prescribing. Do not purchase or inject products advertised online as retatrutide, “research-grade retatrutide” or compounded retatrutide. Speak to an appropriately qualified healthcare professional about licensed weight-management treatments.